Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Is CorMedix Overvalued?

By Modest MoneyStock MarketsApr 02, 2019 02:52PM ET
Is CorMedix Overvalued?
By Modest Money   |  Apr 02, 2019 02:52PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

CorMedix Inc. (NYSE:CRMD) is a commercial-stage pharmaceutical company focused on harnessing its taurolidine technology for the prevention and treatment of infectious and inflammatory diseases. The stock has returned 56% year-to-date. It is currently trading at price to sales ratio of 574.17 and P/B ratio of 41.92.

The company released its fourth quarter 2018 and full year 2018 results on March 14, 2019. Net income was $2.1 million when compared to a net loss of $10.3 million for the same period last year. The improvement was mainly due to the reversal of the clinical trial expenses as a result of the confidential settlement. Operating expenses were $2.1 million compared to $10.4 million in the fourth quarter of 2017. The decrease was primarily due to the decrease in R&D expense of $12.8 million.

For the full year, the company recorded a net loss of $26.8 million or $0.30 per share when compared to a net loss of $32.9 million or $0.60 per share for 2017.

Cash at the end of the fourth quarter was $17.6 million when compared to $10.3 million at the end of December 2017. The management feels that the cash is sufficient until the second quarter of 2020. It also closed the $7.5 million senior secured convertible debt financing with Elliot Associates. The loan has a three-year maturity with an annual interest rate of 10% and is convertible into the company’s common stock at a price equal to $1.50 per share.

The company has announced one-for-five reverse stock split of the Company’s common stock, par value $0.001 with effective from March 26, 2019. Khoso Baluch, CorMedix CEO commented, “We are implementing the reverse stock split as planned so that we have the flexibility to take advantage of future investment opportunities, to possibly attract more institutional interest into our stock, and given our need to have available unissued shares to reserve for past transactions. As our current cash position is expected to finance the Company into the second quarter of 2020, we believe it is a good time to move ahead.” The outstanding shares will be approximately 23.8 million from 119.0 million shares.

Recently, some of the institutional investors have started to increase position in the company. Institutional investors hold around 13% of the company’s stocks. Elliot Associates, L.P. owns about 3.65%, Vanguard holds 3.62%, and Blackrock (NYSE:BLK) holds 2.33%. Some of the company’s insiders have also been increasing positions. Zacks upgraded the stock from a sell rating to a hold rating.

The company’s lead product is Neutrolin in the United States. Neutrolin is currently in Phase 3 clinical study, known as LOCK-IT-100. Neutrolin is a non-antibiotic anti-infective developed as a preventative solution to decrease the threat of infection and blood clots (thrombosis), thereby keeping central venous catheters (CVCs) operating safely and efficiently.

Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for 5 additional years of QIDP market exclusivity in the event of U.S. approval. Neutrolin is CE marked device in Europe and in the post-market studies it showed to reduce catheter-related bloodstream infections by 96% and thrombosis by 96.7% compared to historical benchmarks.

Conclusion: The stock has a market capitalization of about $200 million. It’s a high risk and high return stock. The stock has already moved up in the past several months. The company is betting on the approval of Neutrolin.

Is CorMedix Overvalued?

Related Articles

Is CorMedix Overvalued?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email